Gastrointestinal cancers at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
21 organizations at ASCO 2027 present work in gastrointestinal cancers: 19 drug developers, 1 advocacy group, society, cancer center, publisher or agency and 1 diagnostics, technology or service company. 21 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–19 of 21 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
ALX Oncology South San Francisco, CA | |
Clinical-stage immuno-oncology biotech developing evorpacept, a CD47 blocker, with positive data in HER2-positive gastric cancer. | Booth Exhibiting at Booth IH09 |
Amgen Thousand Oaks, CA | |
Biotechnology drugmaker with cancer medicines for lung, blood and colorectal cancers, including targeted therapies and bispecific T-cell engagers. | Booth Exhibiting at Booth 22025 |
Arcus Biosciences Hayward, CA | |
Clinical-stage biotech with registrational programs in kidney cancer (HIF-2α inhibitor casdatifan) and pancreatic cancer (CD73 inhibitor quemliclustat). | Booth Exhibiting at Booth 32146 |
Astellas Tokyo, Japan | |
Japanese drugmaker with cancer medicines including enzalutamide for prostate cancer, enfortumab vedotin for bladder cancer and zolbetuximab for gastric cancer. | Booth Exhibiting at Booth 15117 |
Bayer Leverkusen, Germany | |
Global drugmaker whose cancer medicines include darolutamide and radium-223 for prostate cancer and regorafenib for colorectal and liver cancers. | Booth Exhibiting at Booth 13059 |
Blue Faery Los Angeles, CA | |
Liver cancer advocacy group funding research, education and patient support for hepatocellular carcinoma. | Booth Exhibiting at Booth 10012 |
Cogent Biosciences Waltham, MA | |
Biotech preparing to launch the KIT inhibitor bezuclastinib for systemic mastocytosis and gastrointestinal stromal tumors. | Booth Exhibiting at Booth 26149 |
Deciphera Pharmaceuticals Waltham, MA | |
Ono Pharmaceutical company marketing kinase inhibitors for gastrointestinal stromal tumors and tenosynovial giant cell tumor. | Booth Exhibiting at Booth 14131 |
Elevar Therapeutics Fort Lee, NJ | |
Oncology biotech developing rivoceranib with camrelizumab as a first-line treatment for liver cancer. | Booth Exhibiting at Booth 34071 |
EMD Serono (Merck KGaA) Boston, MA | |
Healthcare business of Germany's Merck KGaA, with EMD Serono's cancer medicines for colorectal, bladder and lung cancer and SpringWorks' rare tumor drugs. | Booth Exhibiting at Booth 23093 |
Exact Sciences Madison, WI | |
Cancer screening and diagnostics company, now part of Abbott, known for the Cologuard colon cancer screening test and Oncotype DX breast cancer test. | Booth Exhibiting at Booth 22094 |
Exelixis Alameda, CA | |
Oncology drugmaker whose cabozantinib (Cabometyx) treats kidney, liver and thyroid cancers; developing zanzalintinib and other small molecules. | Booth Exhibiting at Booth 27001 Booth Exhibiting at Booth 27059 · Exelixis Medical Affairs |
Ipsen Boulogne-Billancourt, France | |
French specialty drugmaker whose cancer medicines include irinotecan liposome (Onivyde) for pancreatic cancer and treatments for neuroendocrine tumors and prostate cancer. | Booth Exhibiting at Booth 11058 |
Jazz Pharmaceuticals Dublin, Ireland | |
Rare disease and oncology drugmaker with medicines for leukemia, small cell lung cancer and HER2-positive biliary tract cancer. | Booth Exhibiting at Booth 34095 |
Parabilis Medicines Cambridge, MA | |
Clinical-stage biotech using its Helicon peptide platform against hard-to-drug targets, led by the β-catenin inhibitor zolucatetide, with prostate cancer programs. | Booth Exhibiting at Booth 37115 |
Pierre Fabre Lavaur, France | |
French pharmaceutical and dermo-cosmetics company with targeted cancer therapies for melanoma, colorectal and lung cancers, plus breast and hematology medicines. | Booth Exhibiting at Booth 27034 |
RayzeBio San Diego, CA | |
Bristol Myers Squibb company developing actinium-225 radiopharmaceuticals against validated solid tumor targets, led by a program in neuroendocrine tumors. | Booth Exhibiting at Booth 14085 |
Revolution Medicines Redwood City, CA | |
Late-stage oncology company developing RAS(ON) inhibitors such as daraxonrasib for RAS-driven pancreatic, lung and colorectal cancers. | Booth Exhibiting at Booth 21149 |
Servier Suresnes, France | |
Foundation-governed French drugmaker with cancer medicines for leukemia, IDH-mutant glioma, and pancreatic and colorectal cancers. | Booth Exhibiting at Booth 15083 |
Instantly find 20 buyers in gastrointestinal cancers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction